Additionally, we confirmed the prognostic significance of ARPC1B genomic alteration using all cohorts in the TCGA public database for overall prostate cancer Figure 3A and bladder cancer disease progression Figure 3B (9041 patients/9353 samples in 24 studies for prostate and 2678 patients/2769 samples in 17 studies for bladder). Here, ARPC1B is linked to urinary bladder cancer.